Chemotherapy in solitary bone plasmacytoma to prevent evolution to multiple myeloma

• Sophia Ascione,
• Stéphanie Harel,
• Florent L. Besson,
• Rakiba Belkhir,
• Julien Henry,
• Bruno Royer,
• Bertrand Arnulf,
• Xavier Mariette,
• Raphaèle Seror

Affiliations

Sophia Ascione

Department of Rheumatology, AP-HP, Hôpital Bicêtre, Le Kremlin Bicêtre

Stéphanie Harel

Department of Immunohematology, AP-HP, Hôpital Saint-Louis, Paris

Florent L. Besson

Department of Biophysics and Nuclear Medicine-Molecular Imaging, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Orsay, 91401

Rakiba Belkhir

Department of Rheumatology, AP-HP, Hôpital Bicêtre, Le Kremlin Bicêtre

Julien Henry

Department of Rheumatology, AP-HP, Hôpital Bicêtre, Le Kremlin Bicêtre

Bruno Royer

Department of Immunohematology, AP-HP, Hôpital Saint-Louis, Paris

Bertrand Arnulf

Department of Immunohematology, AP-HP, Hôpital Saint-Louis, Paris

Xavier Mariette

Department of Rheumatology, AP-HP, Hôpital Bicêtre, Le Kremlin Bicêtre, France; Center of Immunology of Viral Infections and Auto-immune Diseases (IMVA), INSERM UMR1184, Université Paris-Saclay, Le Kremlin Bicêtre

Raphaèle Seror

Department of Rheumatology, AP-HP, Hôpital Bicêtre, Le Kremlin Bicêtre, France; Center of Immunology of Viral Infections and Auto-immune Diseases (IMVA), INSERM UMR1184, Université Paris-Saclay, Le Kremlin Bicêtre